Headline: Tiziana's Intranasal Foralumab Study Results Published In Peer-Reviewed Journal

Tiziana Pharma Inc. (NASDAQ: TIZN) announced the publication of its Phase 2 clinical trial results for intranasal foralumab in the peer-reviewed journal *Frontiers in Immunology*. The study evaluated the drug’s safety and immunomodulatory effects in patients with autoimmune conditions, with data collected from 68 participants across multiple sites. Results showed a favorable safety profile, with no serious adverse events reported. The treatment demonstrated significant modulation of key immune markers, including reduced levels of pro-inflammatory cytokines. While not a cure, these findings support further investigation into foralumab as a potential non-systemic therapy for autoimmune diseases. The company plans to initiate a larger Phase 3 trial later in 2026, pending regulatory approval. Shares of Tiziana Pharma rose 4.7% in after-hours trading following the announcement.